Investors & Media

Corporate Profile

We are a clinical stage chemoprotection oncology company focused on developing medicines to make chemotherapy safer and thereby more effective to save more patients’ lives.

ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, focusing exclusively on treating patients with p53-mutated cancers.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

  • May 19, 2022
    Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer
  • May 17, 2022
    Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference
  • May 13, 2022
    Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022


  • May 25, 2022 at 1:30 PM EDT

    H.C. Wainwright Global Investment Conference

    Read More
  • May 19, 2022 at 4:00 PM EDT

    Revolutionizing Supportive Care: The Promise of Precision Medicine-Based Chemoprotection for Cancer Patients

    Read More
  • March 28, 2022

    Maxim Group 2022 Virtual Growth Conference

    Read More

To develop a targeted drug that prevents chemotherapy-induced side effects to help patients fight cancer more effectively with a better quality of life


To bring chemoprotection to all patients with p53-mutated cancer regardless of the type of cancer or chemotherapy